SOUTH SAN FRANCISCO, Calif., April 11, 2023 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. ALGSa clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, announced today that the company will present at the European Association for the Study of seven posters co-authored Data from five of its liver disease programs will highlight the Liver (EASL) Congress 2023, taking place June 21-24, 2023 in Vienna, Austria. The presentations will be available on the Scientific presentations and conferences Page on Aligos corporate website after the meeting.

“We are pleased to present seven abstracts at this year’s EASL meeting,” said Lawrence Blatt, Ph.D., MBA, Chairman and CEO of Aligos Therapeutics. “We believe these programs show the potential to serve as world-class connections with significant value for patients and shareholders. We look forward to sharing more details at the time of the conference and additional results later in the year.”

Details of the poster presentation are below.

Chronic hepatitis B

CAM-E ALG-000184
Abstract title: Treatment with the Capsid Assembly Modulator ALG-000184 for up to 24 weeks leads to a dose-dependent reduction in HBsAg in patients with HBeAg-positive chronic hepatitis B
Moderator: Jinlin Hou, MD

siRNA ALG-125755
Abstract title: Safety, pharmacokinetics, and antiviral activity of single ascending doses of ALG-125755, a GalNAc-conjugated small interfering RNA, in patients with chronic hepatitis B
Moderator: Alina Jucov, MD, Ph.D.

Abstract title: Pharmacodynamic stability of ALG-125755, a GalNAc-conjugated siRNA, correlates with total and RNA-induced complex (RISC)-bound siRNA in mouse liver
Moderator: Kusum Gupta

Small molecule PD-L1 inhibitor ALG-093702
Abstract title: Preclinical pharmacokinetic, pharmacodynamic, and efficacy relationships of ALG-093702, a small molecule inhibitor of PD-L1 targeted to the liver, in various in vivo models
Moderator: tongfei…